TransMedics Group (NASDAQ:TMDX) Now Covered by Analysts at Barclays

Research analysts at Barclays started coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Wednesday, Briefing.com reports. The brokerage set an “overweight” rating and a $120.00 price target on the stock. Barclays‘s target price points to a potential upside of 49.48% from the stock’s previous close.

A number of other equities research analysts have also weighed in on TMDX. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. Stifel Nicolaus lifted their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research report on Tuesday, September 8th. Finally, Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $121.00.

TransMedics Group Stock Down 3.3%

TMDX opened at $80.28 on Wednesday. The business’s fifty day simple moving average is $85.86 and its 200 day simple moving average is $84.45. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The stock has a market cap of $2.77 billion, a PE ratio of 20.64, a P/E/G ratio of 1.14 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same quarter in the previous year, the firm earned $0.92 EPS. The business’s quarterly revenue was up 20.7% compared to the same quarter last year. As a group, research analysts expect that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill bought 1,336 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was purchased at an average price of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Braidwell LP lifted its holdings in shares of TransMedics Group by 85.1% during the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares in the last quarter. Deutsche Bank AG bought a new stake in TransMedics Group in the 2nd quarter worth about $14,415,000. Bank of New York Mellon Corp bought a new stake in TransMedics Group in the 2nd quarter worth about $12,869,000. Legal & General Group Plc purchased a new position in TransMedics Group in the 2nd quarter worth about $5,286,000. Finally, FirstWave Capital Management LLC lifted its stake in TransMedics Group by 53.9% during the 2nd quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock valued at $12,702,000 after acquiring an additional 66,972 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.